Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.34.

EBIT: As of FY2026 Q2, the actual value is USD -2.079 M.

Financial Overview (Unaudited)

Cash and Investments

Kiora Pharmaceuticals, Inc. ended the second quarter of 2026 with approximately $16.8 million in cash and short-term investments, an increase from $13.9 million at March 31, 2026. As of June 30, 2026, cash and cash equivalents were $7,076,533, and short-term investments were $9,761,994. This compares to cash and cash equivalents of $8,696,570 and short-term investments of $8,392,513 at December 31, 2025.

Receivables

Collaboration receivables were approximately $1.1 million and tax and other receivables were approximately $1.8 million as of June 30, 2026. Specifically, collaboration receivables were $1,091,385 at June 30, 2026, down from $1,522,770 at December 31, 2025. Tax and other receivables were $1,815,079 at June 30, 2026, slightly up from $1,793,459 at December 31, 2025.

Operating Expenses

For the second quarter of 2026, research and development expenses were approximately $2.1 million before recognizing $1.3 million in reimbursable expenses from Théa, compared to $2.6 million before recognizing $1.7 million in reimbursable expenses for the second quarter of 2025. General and administrative expenses remained consistent at approximately $1.4 million for both the second quarter of 2026 and 2025. Total operating expenses for the three months ended June 30, 2026, were $2,213,771, reduced from $2,396,196 for the same period in 2025. This included general and administrative expenses of $1,383,504 in 2026 versus $1,353,850 in 2025, research and development expenses of $2,077,116 in 2026 versus $2,590,489 in 2025, and collaboration credits of - $1,336,263 in 2026 versus - $1,685,917 in 2025.

Net Loss and Comprehensive Loss

Net loss for the second quarter of 2026 was approximately - $2.1 million, compared with a net loss of - $2.2 million for the second quarter of 2025. Specifically, the net loss was - $2,079,010 for the three months ended June 30, 2026, versus - $2,152,459 for the same period in 2025. The comprehensive loss for the three months ended June 30, 2026, was - $2,106,012, compared to - $2,101,044 for the same period in 2025.

Operating Loss

Kiora Pharmaceuticals, Inc. reported an operating loss of - $2,213,771 for the three months ended June 30, 2026, an improvement from an operating loss of - $2,396,196 for the same period in 2025.

Other Income (Expense)

Total other income, net, was $134,761 for the three months ended June 30, 2026, compared to $131,680 for the same period in 2025. This includes interest income, net, of $146,232 in 2026 versus $225,237 in 2025, and other expense, net, of - $11,471 in 2026 versus - $93,557 in 2025.

Balance Sheet Highlights (June 30, 2026 vs. December 31, 2025)

• Total Current Assets: $21,262,515 at June 30, 2026, down from $21,748,448 at December 31, 2025.
• Total Assets: $23,776,090 at June 30, 2026, down from $24,253,300 at December 31, 2025.
• Total Current Liabilities: $2,370,495 at June 30, 2026, down from $3,631,498 at December 31, 2025.
• Total Liabilities: $6,919,401 at June 30, 2026, down from $8,126,764 at December 31, 2025.
• Total Stockholders’ Equity: $16,856,689 at June 30, 2026, up from $16,126,536 at December 31, 2025.
• Accumulated Deficit: - $158,714,270 at June 30, 2026, compared to - $154,217,276 at December 31, 2025.

Operational Metrics and Pipeline Progress

Kiora Pharmaceuticals, Inc. advanced enrollment in the higher-dose cohort of the Phase 2 ABACUS-2 clinical trial for KIO-301 and continued enrollment in the higher-dose cohort of the Phase 2 KLARITY clinical trial for KIO-104.

Outlook and Guidance

Kiora Pharmaceuticals, Inc. expects its current resources, including collaboration reimbursements and available capital, to fund operations into late 2028. The company secured a private placement for up to $24.0 million in gross proceeds, with $5.0 million received upfront and the remainder contingent on the exercise of near-term milestone-based warrants. Kiora anticipates topline data for the KIO-301 ABACUS-2 trial in the third quarter of 2027 and expects to report initial clinical data for KIO-104 in late 2026.